Oncology, Volume 56, Number 09, September 2011
2011
- 59Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage59
- Downloads48
- Abstract Views11
Newsletter Description
Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunotherapies: Despite progress in screening and therapy, prostate cancer continues to be a leading cause of cancer death among men worldwide New Targeted Therapy Offers Hope in Relapsed Hodgkin and Anaplastic large-Cell Lymphoma: The U.S. Food and Drug Administration (FDA) has approved the first new drug for Hodgkin Lymphoma since 1977 HOUSE CALL: Colorectal Cancer Screening: Risk factors determine who should be screened and how often IN BRIEF: Everolimus may Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer Patients
Bibliographic Details
The University of Texas MD Anderson Cancer Center
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know